Advertisement

Reply to Joep J. de Jong and Ewan A. Gibb’s Letter to the Editor re: Gottfrid Sjödahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.10.035. Neoadjuvant Chemotherapy Response in Muscle-invasive Bladder Cancer: Differences in Intrinsic Biology or Subtyping Nomenclature?

Published:January 14, 2022DOI:https://doi.org/10.1016/j.eururo.2021.12.035
      We wish to thank de Jong and Gibb for their comments and for providing a cross-comparison of LundTax and Decipher genomic subtyping classifier (GSC) subtypes in 505 patients with muscle-invasive bladder cancer. We agree that there may not be a direct contradiction between the data in our study [

      Sjödahl G, Abrahamsson J, Holmsten K, et al. Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.10.035.

      ] and the data reported by Seiler et al. [
      • Seiler R.
      • Ashab H.A.D.
      • Erho N.
      • et al.
      Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy.
      ] or Lotan et al. [

      Lotan Y, de Jong J, Liu VYT, et al. Patients with muscle invasive bladder cancer with non-luminal subtype derive greatest benefit from platinum based neoadjuvant chemotherapy. J Urol. In press. https://doi.org/10.1097/ju.0000000000002261.

      ]. Rather, it is our use of the same words, “luminal” and “basal”, for different molecular groups that causes the studies to reach different conclusions. To clarify, we would like to make four brief comments relevant to this specific issue.
      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to European Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Sjödahl G, Abrahamsson J, Holmsten K, et al. Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.10.035.

        • Seiler R.
        • Ashab H.A.D.
        • Erho N.
        • et al.
        Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy.
        Eur Urol. 2017; 72: 544-554
      2. Lotan Y, de Jong J, Liu VYT, et al. Patients with muscle invasive bladder cancer with non-luminal subtype derive greatest benefit from platinum based neoadjuvant chemotherapy. J Urol. In press. https://doi.org/10.1097/ju.0000000000002261.

        • Kamoun A.
        • de Reyniès A.
        • Allory Y.
        • et al.
        A consensus molecular classification of muscle-invasive bladder cancer.
        Eur Urol. 2020; 77: 420-433
        • Lerner S.P.
        • McConkey D.J.
        • Hoadley K.A.
        • et al.
        Bladder cancer molecular taxonomy: summary from a consensus meeting.
        Bladder Cancer. 2016; 2: 37-47

      Linked Article